Literature DB >> 16623671

Evaluation of primary failure in native AV-fistulae (early fistula failure).

Seiji Ohira1, Tadamasa Kon, Takashi Imura.   

Abstract

The most preferable method of vascular access (VA) in maintenance hemodialysis is a native arteriovenous fistula (AVF). Advanced age as well as the rapid increase in underlying diseases such as diabetic nephropathy and nephrosclerosis in these patients also means that the veins and arteries used to establish the AVF have undergone vascular damage, making construction of an AVF more difficult compared with earlier construction. Although there are various conditions under which arterial superficialization or AV graft must be chosen, it remains the rule that the first choice for VA should be AVF whenever possible. To improve postoperative results, it is necessary to reduce malfunctions immediately following surgery. We conducted a survey of 23 dialysis facilities throughout Japan and analyzed data from the past 3 years regarding the functionality of the AVF at initial puncture following construction of 5007 examples of newly constructed AVFs. Upon initial puncture, primary failure (PF) is defined as those cases in which thrombosis or inadequate blood flow occur. Primary failure occurred in 7.6% of the cases in this series, but there was a wide distribution of PF, 0.8% to 23.6%, because of differences in quality among facilities. This difference in PF is probably affected by technical aspects, the main factor being the characteristics of the patient. Survey responses included: (1) vascular damage of the veins and arteries used in creating the AVF and (2) the suitability of the location chosen for construction. In the data collected, many methods were used to repair those primary AFVs in which PF occurred. The salvage rate was 70%. Currently, the most preferable form of VA is AVF adhering to the principle that the proper timing of the choice and construction of AVF should consider the maturation period. To accomplish this, it is vital that vascular mapping be performed preoperatively to construct the AVF. If PF does occur, the cause should be thoroughly investigated and repairs made effectively.

Entities:  

Mesh:

Year:  2006        PMID: 16623671     DOI: 10.1111/j.1542-4758.2006.00091.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  6 in total

1.  Early use of autogenous arteriovenous fistula in patients with urgent hemodialysis.

Authors:  Wanjun Ren; Huili Jiang; Yuejuan Du; Fang Liu; Xiaoping Wang; Dongmei Xu
Journal:  Int Urol Nephrol       Date:  2017-03-02       Impact factor: 2.370

2.  Arteriovenous fistulas as vascular access for hemodialysis: The preliminary experience at the University Hospital of the West Indies, Jamaica.

Authors:  Shamir O Cawich; Hilary Brown; Allie Martin; Mark S Newnham; Rageev Venugopal; Eric Williams
Journal:  Int J Angiol       Date:  2009

3.  Thrombophilias and arteriovenous fistula dysfunction in maintenance hemodialysis.

Authors:  Ramazan Danis; Sehmus Ozmen; Davut Akin; Sabri Batun; Serdar Kahvecioglu; Abdullah Altintas; Mehmet E Yilmaz; Adil Polat
Journal:  J Thromb Thrombolysis       Date:  2008-03-25       Impact factor: 2.300

4.  Preoperative ultrasonographic examination of the radial artery and the cephalic vein and risks of dialysis arterio-venous fistula dysfunction.

Authors:  Krzysztof Bojakowski; Ewa Gorczyca-Wiśniewska; Maciej Szatkowski; Jerzy Walecki; Piotr Andziak
Journal:  Pol J Radiol       Date:  2010-01

5.  Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis.

Authors:  Ju-Young Moon; Hyae Min Lee; Sang-Ho Lee; Tae-Won Lee; Chun-Gyoo Ihm; Young-Il Jo; Sang-Woong Han; Sug-Gyun Shin
Journal:  Kidney Res Clin Pract       Date:  2015-02-23

6.  Association of early loss of primary functional patency of arteriovenous access with mortality in incident hemodialysis patients: A nationwide population-based observational study.

Authors:  Chung-Kuan Wu; Chia-Hsun Lin; Chih-Cheng Hsu; Der-Cherng Tarng; Chew-Teng Kor; Yi-Chun Chen; Chia-Lin Wu; Chia-Chu Chang
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.